| 摘要: | Nonprofit partnership of chemical institutes of Russian Academy of Sciences (RAS) �Orchemed� (Organic Chemistry and Medicine) was established in 2005 as a mechanism to transfer innovative drug discovery technologies to market needs. To the beginning of 2011, the consortium includes 13 institutes-members from the scientific centers of RAS - Moscow, Chernogolovka, Ekaterinburg, Novosibirsk, Kazan, Ufa, Irkutsk, Ivanovo, Syktyvkar. Orchemed's mission is to identify and promote prospective drug discovery tecechnologies developed in Russian academic institutes, and effectively transfer them to national and global pharmaceutical industry. The Orchemed's institutes possess the full cycle of preclinical drug discovery technologies, such as computational virtual screening; libraries of synthetic amnd natural corompounds; biological screening and med-chem optimization; studies of molelecular mechanisms of drug action; studies of phys-chem, pharmacological, metabolic profile of potential drugs; development of advanced drug delivery systems; preclinical animal studies; advanced IT-platform for project management. Using these advanced technologies, the institutes developed a lot of interesting molecules, potential drug candidates, which are now presented in Orchemed's portfolio. Among them are >50 projects in actual pharmacological areas, including antiviral, , antitumor, cardiovascular, anti-inflammatory, antineurodegenerative and others. Orchemed is now a well recognized academic expert group in Russia. Scientists of Orchemed work as invited experts for State Duma, government, business groups, mass media, etc. Orchemed is one of official codevelopers of Strategy of Development of Pharmaceutical Industry of Russian Federation in 2008-2020 (Pharma-2020); initiator of strategic national projects, such as National bioscreening network; a strategic partner of many big Russian innovative (bio)pharmaceutical companies. Dr. Balakin will present the latest developments of consortium in the field of innovative drug discovery, with emphasis on novel projects available for commercialization. |
